F. Franzoso

Transcriptomic signatures of hydroxyurea response in sickle cell disease

Hydroxyurea (HU) has been widely used as a first-line therapy for sickle cell disease (SCD), an autosomal recessive monogenic disorder characterized by abnormal haemoglobin and chronic haemolysis. However, its multiple mechanisms of action, particularly those related to SCD pathogenesis, remain incompletely under...